New pharmacologic approaches to therapy for age-related macular degeneration

BioDrugs

Volumn 20, Issue 3, 2006, Pages 167-179

  Eter, Nicole ^a   Krohne, Tim U ^a   Holz, Frank G ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANECORTAVE; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; COPPER; CORTICOSTEROID; DORZOLAMIDE; FLAVONOID; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; METHOTREXATE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; POLYPHENOL; PROSTAGLANDIN SYNTHASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; SQUALAMINE; TRIAMCINOLONE; VASCULOTROPIN; XANTHOPHYLL; ZEAXANTHIN; ZINC;

CATARACT; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHTHALMITIS; GENE THERAPY; HUMAN; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION;

EID: 33744935522     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620030-00004     Document Type: Review

References (119)

1. Bird A. Age-related macular disease. Br J Ophthalmol 1996; 80 (1): 2-3
2. Holz FG, Pauleikhoff D. Clinical manifestations. In: Holz FG, Pauleikhoff D, Spaide RF, et al., editors. Age-related macular degeneration. Berlin: Springer, 2004: 73-90
3. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45 (2): 115-34
4. Spaide RF, Ho-Spaide WC, Browne RW, et al. Characterization of peroxidized lipids in Bruch's membrane. Retina 1999; 19 (2): 141-7
5. Schmidt-Erfurth U. Nutrition and retina. Dev Ophthalmol 2005; 38: 120-47
6. Flamm P. Zur Therapie der degenerativen Makulopathie mit Cosaldon A + E. Klin Monatsbl Augenheilkd 1987; 190 (1): 59-66
7. Karcioglu Z. Zinc in the eye. Surv Ophthalmol 1982; 27: 114-22
8. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration. Arch Ophthalmol 1988; 106 (2): 192-8
9. Kaminski MS, Yolton DP, Jordan WT, et al. Evaluation of dietary antioxidant levels and supplementation with ICAPS-Plus and Ocuvite. J Am Optom Assoc 1993; 64 (12): 862-70
10. Holz FG, Wolfensberger TJ, Piguet B, et al. Oral zinc-therapy in age-related macular degeneration: a double blind study. Ger J Ophthalmol 1993; 2 Suppl. 2: 391
11. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmol 2003; 110: 979-86
12. The AREDS Study Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119 (10): 1417-36
13. Schutt F, Pauleikhoff D, Holz FG. Vitamine und Spurenelemente bei altersabhängiger Makuladegeneration. Aktuelle Empfehlungen, basierend auf den Resultaten der AREDS-Studie. Ophthalmologe 2002; 99: 301-3
14. Seigel D. AREDS investigators distort findings. Arch Ophthalmol 2002; 120 (1): 100-1
15. De Luca LM, Ross SA. Beta-carotene increases lung cancer incidence in cigarette smokers. Nutr Rev 1996 Jun; 54 (6): 178-80
16. Augustin AJ, Schmidt-Erfurth U. Critical comments on the ARED study [in German]. Ophthalmologe 2002; 99 (4): 299-300
17. Pauleikhoff D, van Kuijk FJ, Bird AC. Makul̈ares pigment und altersabhängige makuladegeneration. Ophthalmologe 2001; 98: 511-9
18. Hammond B, Caruso-Avery M. Macular pigment optical density in a Southwestern sample. Invest Ophthalmol Vis Sci 2000; 41 (6): 1492-7
19. Beatty S, Murray IJ, Henson DB, et al. Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001; 42 (2): 439-46
20. Hammond Jr BR, Johnson EJ, Russell RM, et al. Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 1997; 38 (9): 1795-801
21. Berendschot TT, Goldbohm RA, Klopping WA, et al. Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest Ophthalmol Vis Sci 2000; 41 (11): 3322-6
22. Landrum JT, Bone RA, Joa H, et al. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 1997; 65 (1): 57-62
23. Bone RA, Landrum JT, Guerra LH, et al. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003; 133 (4): 992-8
24. Falsini B, Piccardi M, Iarossi G, et al. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 2003; 110 (1): 51-60
25. Ey C. Future clinical trials: AREDS II with lutein/zeaxanthin [E-abstract 1228]. Ophthalmol Vis Sci 2005; 46 Suppl.
26. Majji AB, Hayashi A, Kim HC, et al. Inhibition of choriocapillaris regeneration with genistein. Invest Ophthalmol Vis Sci 1999; 40 (7): 1477-86
27. Nakajima M, Cooney MJ, Tu AH, et al. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci 2001; 42 (9): 2110-4
28. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995; 86 (7): 2488-93
29. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995; 125 (3 Suppl.): 790-7
30. Uyama M, Takahashi K, Ida N, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol 2000 Sep; 84 (9): 1018-23
31. Chang TS, Hay D, Courtright P. Age-related macular degeneration in Chinese-Canadians. Can J Ophthalmol 1999 Aug; 34 (5): 266-71
32. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 137 (4): 615-24
33. Blanco-Colio LM, Tunon J, Martin-Ventura JL, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63 (1): 12-23
34. Veillard N, Mach F. Statins: the new aspirin? Cell Mol Life Sci 2002; 51: 1771-86
35. The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992; 110 (12): 1701-8
36. Curcio CA, Presley JB, Malek G, et al. Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy. Exp Eye Res 2005 Dec; 81 (6): 731-41
37. Malek G, Li CM, Guidry C, et al. Apolipoprotein B in cholesterol- containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol 2003 Feb; 162 (2): 413-25
38. Curcio CA, Millican CL, Bailey T, et al. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001 Jan; 42 (1): 265-74
39. Curcio CA, Millican CL, Bailey T, et al. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42 (1): 265-74
40. Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001; 323: 375-6
41. Yang R, McCollum G, Bingaman D, et al. Inhibition of VEGF-induced endothelial cell proliferation and differentiation by steroidal and non-steroidal COX inhibitors with variable COX-1/COX-2 selectivity [E-abstract 1914]. Invest Ophthalmol Vis Sci 2004; 45 Suppl.
42. Csaky KG. Phase II trial of celebrex in photodynamic therapy (C-PDT) for neovascular age-related macular degeneration (AMD): rationale and baseline characteristics [E-abstract 1186]. Invest Ophthalmol Vis Sci 2004; 45 Suppl.
43. Lutty G, Grunwald J, Majji AB, et al. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis 1999; 5: 35
44. Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol 2001; 119 (8): 1143-9
45. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 1988; 128 (4): 700-10
46. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110 (5-6): 255-8
47. Harris A, Ciulla TA, Pratt LM, et al. The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration. Br J Ophthalmol 2003; 87 (6): 753-7
48. Pauleikhoff D, Chen JC, Chisholm IH, et al. Choroidal perfusion abnormality with age-related Bruch's membrane change. Am J Ophthalmol 1990; 109 (2): 211-7
49. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19: 331-58
50. Miller J, Shima DT, Tolentino M, et al. Inhibition of VEGF prevents ocular neovascularization in a monkey model [abstract]. Invest Ophthalmol Vis Sci 1995; 36: 401
51. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157 (1): 135-44
52. Hruby K. Aussichten und Grenzen der Behandlung seniler Makulopathien mit Phosphatiden. Wien Klin Wochenschr 1977; 89 (13): 439-42
53. Garrett K, Shen WY, Rakoczy PE. In vivo use of oligonucleotides to inhibit choroidal neovascularization in the eye. J Gene Med 2001; 3: 373-83
54. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351 (27): 2805-16
55. D'Amico D, Bird AC. VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): safety evaluation from the pivotal Macugen™ (pegaptanib sodium) clinical trials [E-abstract 2363]. Invest Ophthalmol Vis Sci 2004; 45 Suppl.
56. Pfizer Inc. Treatment results with MACUGEN® (pegaptanib sodium injection). MACUGEN [online]. Available from URL: http://www.macugen.com/ treatment.asp [Accessed 2006 Apr 28]
57. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120 (3): 338-46
58. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. Epub 2006 Feb 13
59. Heier JS. Review of Lucentis™ (randibizumab, rhuFab V2) phase I/II trial results: 6-month treatment of exsudative AMD [E-abstract 1109]. Invest Ophthalmol Vis Sci 2004; 45 Suppl.
60. Novartis. New data from two leading clinical studies show Lucentis® is first therapy to improve vision in patients with wet age-related macular degeneration (AMD) [press release]. Novartis, 2005 Jul 18 [online]. Available from URL: http://dominoext.novartis.com/NC/NCPRRE01.nsf [Accessed 2006 Apr 28]
61. Novartis. Preliminary data from second pivotal phase III study showed Lucentis® maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD) [press release]. Novartis, 2005 Nov 7 [online]. Available from URL: http://dominoext.novartis.com/NC/NCPRRE01.nsf [Accessed 2006 Apr 28]
62. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005 Jul 29; 333 (2): 328-35
63. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112 (6): 1035-47
64. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36 (4): 331-5
65. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005 Jul-Aug; 36 (4): 336-9
66. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006 Mar; 26 (3): 279-84
67. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006 Mar; 26 (3): 275-8
68. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 Mar; 113 (3): 363-72
69. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004; 4 Suppl. 2: S81-5
70. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99 (17): 11393-8
71. Saishin Y, Takahashi K, Lima e Silva R, et al. VEGF-Trap (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195 (2): 241-8
72. Ciulla TA, Criswell MH, Danis RP, et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003; 23 (6): 808-14
73. Genaidy M, Kazi AA, Peyman GA, et al. Effect of squalamine on iris neovascularization in monkeys. Retina 2002; 22 (6): 772-8
74. Higgins RD, Sanders RJ, Yan Y, et al. Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 2000; 41 (6): 1507-12
75. Genaera. Genaera Corporation presents clinical results for EVIZON™ for treatment of age-related macular degeneration at the annual ASRS meeting [press release]. Genaera, 2005 Jul 18 [online]. Available from URL: http://www.genaera.com/pressreleases_toc.html [Accessed 2006 Apr 28]
76. Stellmach V, Crawford SE, Zhou W, et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 2001; 98 (5): 2593-7
77. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43 (7): 2428-34
78. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43 (6): 1994-2000
79. Holekamp NM. Deficiency of anti-angiogenic pigment epithelial-derived factor in the vitreous of patients with wet age-related macular degeneration. In: Proceedings of the 34th Annual Scientific Meeting of the Retina Society; 2001 Sep 13-16; Chicago (IL). Boston (MA) The Retina Society, 2001: 66
80. Renno RZ, Youssri AI, Michaud N, et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43 (5): 1574-80
81. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12 (16): 2029-32
82. Harris A, Arend O, Arend S, et al. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand 1996; 74 (6): 569-72
83. Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998; 39 (11): 2194-200
84. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878: 236-70
85. Holz FG, Miller DW. Pharmacological therapy for age-related macular degeneration: current developments and perspectives [in German]. Ophthalmologe 2003 Feb; 100 (2): 97-103
86. Aeterna Zentaris. Neovastat® product sheet. Aeterna Zentaris [online]. Available from URL: http://www.aeternazentaris.com [Accessed 2006 Apr 28]
87. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230 (4732): 1375-8
88. BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997; 38 (10): 1954-62
89. Penn JS, Rajaratnam VS, Collier RJ, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 42 (1): 283-90
90. Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999; 40 (9): 2158-62
91. McNatt LG, Weimer L, Yanni J, et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 1999; 15 (5): 413-23
92. McNatt LG, Lane D, Clark AF. Angiostatic activity and metabolism of cortisol in the chorioallantoic membrane (CAM) of the chick embryo. J Steroid Biochem Mol Biol 1992; 42 (7): 687-93
93. Oikawa T, Hiragun A, Yoshida Y, et al. Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene and its inhibition by medroxyprogesterone acetate: possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett 1988; 43 (1-2): 85-92
94. Proia AD, Hirakata A, McInnes JS, et al. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 1993; 57 (6): 693-8
95. D'Amico DJ, Goldberg MF, Hudson H, Anecortave Acetate Clinical Study Group, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003 Feb; 23 (1): 14-23
96. D'Amico DJ, Goldberg MF, Hudson H, Anecortave Acetate Clinical Study Group, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003 Dec; 110 (12): 2372-83
97. Schmidt-Erfurth U, Michels S, Michels R, et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005; 15 (4): 482-5
98. Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119 (3): 399-404
99. Spandau U, Sauder G, Jonas JB, et al. Angiostatic effect of crystalline triamcinolone acetonide on ocular neovascularization in vivo [E-abstract 2497]. Invest Ophthalmol Vis Sci 2002; 43 Suppl.
100. Gillies M, Simpson J, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121 (5): 667-73
101. Roth D, Spirn M, Yarian DL, et al. Intravitreal triamcinolone injection for the treatment of occult choroidal neovascularization associated with age-related macular degeneration [E-abstract 2500]. Invest Ophthalmol Vis Sci 2002; 43 Suppl.
102. Moon S, Mieler WF, Holz ER. Pilot study of intravitreal injektion of triamcinolone acetonide in exsudative age-related macular degeneration [E-abstract 1220]. Invest Ophthalmol Vis Sci 2002; 43 Suppl.
103. Jonas J, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exsudative age-related macular degeneration. Br J Ophthalmol 2003; 87: 462-8
104. Lambert V, Munaut C, Noel A, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15 (6): 1021-7
105. Slakter JS, Bochow TW, D'Amico DJ, Anecortave Acetate Clinical Study Group, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006 Jan; 113 (1): 3-13
106. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110 (8): 1517-25
107. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44 (10): 4473-80
108. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88 (3): 344-7
109. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112 (2): 301-4
110. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2: 733-40
111. Karl S, Bindewald A, Roth F, et al. Intravitreale methotrexat-injektionen bei choroidalen neovaskularisationen im rahmen der altersabḧangigen makuladegeneration (AMD) [poster 158]. Proceedings of the German Society of Ophthalmology (DOG) 2004 Annual Meeting; 2004 Sep 23-26; Berlin
112. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208 (4443): 516-8
113. Engler CB, Sander B, Koefoed P, et al. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration: a pilot investigation. Acta Ophthalmol (Copenh) 1993; 71 (1): 27-31
114. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326 (22): 1456-63
115. Fung WE. Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol 1991; 112 (3): 349-50
116. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebocontrolled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. Arch Ophthalmol 1997; 115 (7): 865-72
117. Maguire M, Fine SL, Maguire AM, et al. AMDATS Research Group: results of the age-related macular degeneration and thalidomide study (AMDATS) [abstract]. Invest Ophthalmol Vis Sci 2001; 42: 233
118. Reich S, Fosnot J, Akiko K, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-6
119. Tolentino MJ, Brucker AJ, Joshua F, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal Neovascularization. Retina 2004; 24: 132-8